Hedge fund manager Kyle Bass and IP Nav’s Erich Spangenberg have filed a second inter partes review petition against a patent owned by Acorda Therapeutics, as part of a strategy BIO said had “opened a new door to abuse of the US patent system”
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact
IP leaders at Brandsmiths and Bird & Bird, who were on opposing sides at the UK Supreme Court in Iconix v Dream Pairs, unpick the landmark case and its ramifications